Biliary Diarrhea Diagnosis and Management

Diagnostic Approach

The American Gastroenterological Association recommends considering bile acid diarrhea (BAD) in patients with chronic diarrhea and risk factors such as terminal ileal resection, cholecystectomy, or abdominal radiotherapy, and diagnostic testing with SeHCAT or serum 7α-hydroxy-4-cholesten-3-one (C4) is preferred over empiric treatment 1
High-risk patients for BAD include those with terminal ileal resection, cholecystectomy, abdominal radiotherapy, Crohn's disease without active inflammation, irritable bowel syndrome with diarrhea (IBS-D), or functional diarrhea 1, 2

The Canadian Association of Gastroenterology recommends cholestyramine as initial therapy for confirmed or suspected BAD, starting at 4 g once or twice daily with meals, then titrating to 2-12 g/day based on symptom response 1, 3
Cholestyramine achieves clinical response in approximately 70% of patients overall, with response rates varying by SeHCAT retention 4, 3

The American College of Gastroenterology recommends maintaining treatment at the lowest effective dose to minimize side effects and cost, and considering a trial of intermittent, on-demand administration rather than continuous therapy 1, 5
Approximately 39-94% of patients experience recurrent diarrhea when cholestyramine is withdrawn, depending on underlying cause and severity 3

The European Society for Clinical Nutrition and Metabolism recommends monitoring for fat-soluble vitamin deficiencies (vitamins A, D, E, K) in patients on long-term cholestyramine therapy, as prolonged use causes malabsorption in 20% of patients 3
The National Institute for Health and Care Excellence recommends checking serum bicarbonate and chloride levels to detect hyperchloremic metabolic acidosis, particularly in patients with renal impairment or volume depletion 3